Ftse Mib
33.220,31
-0,29%
DAX
18.067,91
-0,31%
S&P 500
5.487,03
0,25%
NASDAQ
17.862,23
0,03%
Bitcoin
64.934,70
-0,05%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Immunovant Inc (IMVT) Immunovant Inc (IMVT) Notizie

Immunovant Inc

IMVT
26,19
-0,61 (-2,28%)
19 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
29/5/202422:36EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/5/202422:17EDGAR2Form 8-K - Current report
29/5/202422:01GLOBEImmunovant Provides Corporate Updates and Reports Financial..
24/5/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202422:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/3/202412:30GLOBEImmunovant Awarded U.S. Patent for IMVT-1402
23/2/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202414:47EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202413:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/2/202413:02EDGAR2Form 8-K - Current report
29/1/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202413:29EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/1/202422:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202414:08EDGAR2Form 8-K - Current report
03/1/202414:00GLOBEImmunovant to Present at the 42nd Annual J.P. Morgan..
20/12/202323:40DJNImmunovant Gets Positive Data From Graves' Disease Treatment..
20/12/202322:37EDGAR2Form 8-K - Current report
20/12/202322:30GLOBEImmunovant Reports Positive Initial Phase 2 Results for..
28/11/202313:43EDGAR2Form 8-K - Current report
28/11/202313:00GLOBERoivant Announces Positive IMVT-1402 Initial 600 mg MAD..
24/11/202320:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/11/202320:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/11/202320:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/11/202320:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202314:00GLOBEImmunovant to Present at Upcoming Investor Conferences
09/11/202314:49EDGAR2Form S-3ASR - Automatic shelf registration statement of..
09/11/202313:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:06EDGAR2Form 8-K - Current report
09/11/202313:00GLOBEImmunovant Reports Financial Results and Provides Corporate..
20/10/202322:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/10/202322:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202323:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202323:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202322:52GLOBEImmunovant Announces Closing of Upsized Common Stock..
29/9/202322:48EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/9/202323:23EDGAR2Form 8-K - Current report
28/9/202312:09EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
28/9/202305:41GLOBEImmunovant Announces Pricing of $450 Million Common Stock..
26/9/202323:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/9/202323:00GLOBEImmunovant Announces Proposed Offering of $300 Million of..
26/9/202313:45EDGAR2Form 8-K - Current report
26/9/202312:00GLOBEImmunovant Announces Positive Initial IMVT-1402 Phase 1 SAD..
26/9/202305:01GLOBEImmunovant to Host Conference Call and Webcast to Report..
Apertura: 26,77 Min: 26,09 Max: 27,25
Chiusura: 26,80

La tua Cronologia

NASDAQ
IMVT
Immunovant
BIT
NSCIT0550334
KME
LATK
PSIXUSDT
ProperSix
COIN
BIFIIBTC
BiFi
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network